CTLA4 and combined immunodeficiency: Group 1 (Rituximab) consisted of 11 girls and 5 boys whose median age was 12 (6–18) years, and the PID/genetic defect distribution was as follows: del22 (3/16), NFkB1/2 (NFkB1/2) deficiency (2/16), CTLA4 (CTLA4) deficiency (1/16), Nijmegen syndrome (NBS) (1/16), LRBA (LRBA) deficiency (1/16), Artemis deficiency (DCLRE1C) (1/16), and CID without genetic defect (7/16).